论文部分内容阅读
血脂康为近年来新开发研制的降血脂药物,临床证明该药具有明显的降低总胆固醇、甘油三酯和升高高密度脂蛋白的作用且未见毒副反应。通过动物实验发现该药具有抑制脂质在肝脏沉积的作用。我科从1997年5月～1998的2月对39例脂肪肝合并高脂血症病人给予血脂康(北大维信生物科技有限公司产品)治疗,现报告如下。 1 临床资料与方法 1.1 病例选择 选择符合脂肪肝合并高脂血症的门诊病人39人,男20例,女19例,年龄26～65岁,平均41.3岁。临床表现为不同程度的乏力、食欲不振、右上腹不适、肝区疼痛,甚至恶心、呕吐。
Xuezhikang is newly developed hypolipidemic drug developed in recent years. It has been clinically proven that the drug has obvious effects of reducing total cholesterol, triglyceride and increasing high density lipoprotein with no toxic or side effects. The animal experiments found that the drug has the effect of inhibiting lipid deposition in the liver. Our department from May 1997 to February 1998 39 cases of fatty liver with hyperlipidemia patients given Xuezhikang (North Watson Biological Technology Co., Ltd.) treatment, are as follows. 1 Clinical data and methods 1.1 Case Selection In accordance with the selection of fatty liver patients with hyperlipidemia outpatient 39, 20 males and 19 females, aged 26 to 65 years, mean 41.3 years. Clinical manifestations of varying degrees of fatigue, loss of appetite, right upper quadrant discomfort, liver pain, and even nausea and vomiting.